EyePoint Pharmaceuticals, Inc. (PV3B.F)

7.84 -0.01 (-0.18%) As of 03:29PM CEST. Market open.

EyePoint Pharmaceuticals, Inc.

480 Pleasant Street
Suite A-210
Watertown, MA 02472
United States
617 926 5000
https://eyepointpharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 121

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Jay S. Duker M.D.	President, CEO & Director	1.21M	N/A	1959
Mr. George O. Elston	Executive VP & CFO	843.58k	N/A	1965
Dr. John B. Landis M.S., Ph.D.	Interim Head of R&D and Director	62.9k	N/A	1953
Mr. Michael J. Maciocio	Senior Vice President of Manufacturing & Operations	N/A	N/A	N/A
Mr. Ron I. Honig Esq.	Chief Legal Officer & Company Secretary	N/A	N/A	N/A
Ms. Jennifer Leonard	Chief People Officer & Senior VP of IT	N/A	N/A	N/A
Mr. David Scott Jones M.A.	Senior VP & Chief Commercial Officer	626.23k	N/A	1967
Mr. Michael Pine	Chief Business Officer	712.67k	N/A	1977
Ms. Isabelle Lefebvre	Chief Regulatory Officer	N/A	N/A	N/A
Dr. Marcia Sellos-Moura Ph.D.	Senior Vice President of Program Leadership	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

Corporate governance

EyePoint Pharmaceuticals, Inc.’s ISS governance QualityScore as of 1 June 2024 is 6. The pillar scores are Audit: 9; Board: 3; Shareholder rights: 4; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.